Elle Communications is Agency of Record for FDA-Cleared Neurostimulation Device
Dolphin (NASDAQ:DLPN) subsidiary Elle Communications is agency of record for NET Recovery as the company rolls out a national treatment program for the FDA-cleared NET Device™ on November 19, 2025.
A new peer-reviewed study in Frontiers in Psychiatry reported that patients using the NET Device for more than 24 hours during opioid withdrawal had significantly fewer days of opioid and stimulant use in the three months after discharge and showed greater residential-treatment retention. The launch expands access to non-pharmacologic, guided at-home and clinic-based withdrawal support and includes PR, thought leadership, funding-announcement strategy, and integrated communications from Elle.
Dolphin (NASDAQ:DLPN) la controllata Elle Communications è l'agenzia incaricata per NET Recovery mentre l'azienda avvia un programma nazionale di trattamento per il NET Device™ approvato dalla FDA il 19 novembre 2025.
In Frontiers in Psychiatry è stato pubblicato uno studio peer-reviewed che ha riportato che i pazienti che usano il NET Device per oltre 24 ore durante il ritiro da oppioidi hanno significativamente meno giorni di uso di oppioidi e stimolanti nei tre mesi successivi al ricovero e hanno mostrato una maggiore permanenza nel trattamento residenziale. Il lancio amplia l'accesso a supporto al ritiro non farmacologico, guidato a casa e in clinica e comprende relazioni stampa, leadership di pensiero, strategia di annuncio dei finanziamenti e comunicazioni integrate da Elle.
Dolphin (NASDAQ:DLPN) la subsidiaria Elle Communications es la agencia de registro de NET Recovery mientras la empresa implementa un programa nacional de tratamiento para el NET Device™ aprobado por la FDA el 19 de noviembre de 2025.
Un nuevo estudio revisado por pares en Frontiers in Psychiatry informó que pacientes que usan el NET Device por más de 24 horas durante el síndrome de retirada de opioides tuvieron significativamente menos días de consumo de opioides y estimulantes en los tres meses siguientes al alta y mostraron una mayor retención en el tratamiento residencial. El lanzamiento amplía el acceso a apoyo de retirada no farmacológico, guiado en casa y en clínica e incluye relaciones públicas, liderazgo de pensamiento, estrategia de anuncio de financiación y comunicaciones integradas de Elle.
Dolphin (NASDAQ:DLPN) 자회사 Elle Communications는 NET Recovery의 기록 대행 에이전시로, FDA 승인 NET Device™에 대한 전국적 치료 프로그램을 2025년 11월 19일에 론칭합니다.
Frontiers in Psychiatry에 실린 새로운 동료 심사 연구는 오피오이드 금단 중에 24시간 이상 NET Device를 사용하는 환자들이 퇴원 후 3개월 동안 오피오이드 및 자극제 사용일이 유의하게 적었고 주거 치료 유지율이 더 높았다고 보고했습니다. 이 출시는 약물 비의존적, 가정 및 클리닉 기반의 금단 지원에 대한 접근을 확장하며 Elle의 PR, 사유 리더십, 자금 조달 발표 전략, 통합 커뮤니케이션을 포함합니다.
Dolphin (NASDAQ:DLPN) filiale Elle Communications est l'agence attitrée de NET Recovery alors que l'entreprise déploie un programme national de traitement pour le NET Device™ approuvé par la FDA le 19 novembre 2025.
Une nouvelle étude évaluée par des pairs dans Frontiers in Psychiatry a rapporté que les patients utilisant le NET Device pendant plus de 24 heures lors du sevrage aux opioïdes avaient significativement moins de jours d'utilisation d'opioïdes et de stimulants au cours des trois mois suivant la sortie et montraient une meilleure rétention dans le traitement résidentiel. Le lancement étend l'accès à un soutien au sevrage non pharmacologique, guidé à domicile et en clinique, et comprend les relations publiques, le leadership éclairé, une stratégie d'annonce de financement et des communications intégrées d'Elle.
Dolphin (NASDAQ:DLPN) Tochtergesellschaft Elle Communications ist die Agentur des NET Recovery, während das Unternehmen ein landesweites Behandlungsprogramm für das von der FDA genehmigte NET Device™ am 19. November 2025 einführt.
Eine neue von Fachkollegen begutachtete Studie in Frontiers in Psychiatry berichtete, dass Patienten, die das NET Device während der Opioid-Entzugssymptomatik länger als 24 Stunden verwendeten, signifikant weniger Tage Opioid- und Stimulantienkonsum in den drei Monaten nach der Entlassung hatten und eine höhere Wohntherapieretention zeigten. Der Start erweitert den Zugang zu nicht-pharmakologischer, angeleiteter Unterstützung zu Hause und in der Klinik und umfasst PR, Thought Leadership, Finanzierungsankündigungsstrategie und integrierte Kommunikation von Elle.
Dolphin (NASDAQ:DLPN) هي شركة فرعية Elle Communications هي الوكالة المسؤولة عن NET Recovery بينما تطرح الشركة برنامج علاج وطني لـ NET Device™ المعتمد من FDA في 19 نوفمبر 2025.
دراسة جديدة من مراجعين أُجريت في Frontiers in Psychiatry أظهرت أن المرضى الذين استخدموا NET Device لأكثر من 24 ساعة أثناء الانسحاب من المواد الأفيونية كان لديهم أيام استخدام أقل بشكل ملحوظ بالنسبة للمورفين والمنبهات خلال ثلاثة أشهر بعد الخروج وظهروا احتفاظًا أعلى في العلاج السكني. يوسع الإطلاق الوصول إلى دعم الانسحاب غير الدوائي، الموجّه منزليًا وفي العيادة، ويتضمن العلاقات العامة، وقيادة الفكر، واستراتيجية إعلان التمويل، والتواصل المتكامل من Elle.
- Device FDA-cleared for reducing opioid withdrawal symptoms
- Study: >24-hour NET Device use linked to fewer opioid and stimulant use days in 3 months
- National rollout enables secure, guided at-home non-pharmacologic withdrawal support
- Regulatory clearance limited to opioid withdrawal, not approved for stimulant use
- Study described as showing potential reduction in stimulant use, not an approved indication
Insights
FDA-cleared device shows peer-reviewed evidence of reduced opioid and stimulant use; national rollout targets access barriers.
The NET Device™ is described as an FDA-cleared transcutaneous alternating current stimulator intended to reduce opioid withdrawal symptoms when used with standard symptomatic medications and supervised clinical care. A peer-reviewed study in Frontiers in Psychiatry reported that patients using the device for more than 24 hours during opioid withdrawal had significantly fewer days of opioid and stimulant use in the three months after discharge and better retention in residential treatment.
Practical dependencies and risks are explicit in the release: the clearance covers opioid withdrawal symptom reduction only, while the stimulant-use findings are presented as emerging data and potential. Successful national uptake will rely on the new treatment program’s ability to expand access across cost, geography, and stigma barriers and on communications and stakeholder engagement with clinicians, payors, policymakers, and people in recovery that the agency is executing.
Watch for concrete follow-ups over the next 6–12 months: broader clinical evidence that confirms stimulant-use effects, dissemination metrics for the national treatment program (patient reach and retention), and any regulatory or payer decisions referencing the device’s use beyond opioid withdrawal.
NET Recovery Announces National Treatments Amid Addiction Crisis
LOS ANGELES, CA / ACCESS Newswire / November 19, 2025 / Elle Communications, a subsidiary of Dolphin (NASDAQ:DLPN), is the agency of record for NET Recovery, an FDA-cleared neurostimulation device 1 for which recent research demonstrated the potential to reduce both opioid and stimulant use 2.
Amid record-high overdose deaths and no FDA-approved medications for stimulant addiction, a new peer-reviewed study published in Frontiers in Psychiatry has found that NET Recovery's the NET Device™ has the potential to significantly reduce both opioid and stimulant use following treatment. The release of these findings coincides with the company's national launch of a treatment program, which expands access to evidence-based, non-pharmacological support across the U.S.
The study, the first to show that a medical device may reduce both opioid and stimulant use, found that patients who used the NET Device™ for more than 24 hours during opioid withdrawal reported significantly fewer days of opioid and stimulant use in the three months after discharge. Patients receiving longer stimulation also demonstrated greater retention in residential treatment, a critical predictor of long-term recovery.
While the NET Device™ is FDA-cleared for reducing symptoms of opioid withdrawal, emerging data indicate the technology may also help stabilize patients using other substances such as cocaine and methamphetamine, addressing the polysubstance addiction patterns now driving nearly half of all fatal overdoses.
"This study reinforces what we're seeing in treatment settings across the country, that when people can find relief from withdrawal quickly and safely, they're able to stay in care longer and build the stability needed for recovery," said Joe Winston, CEO and co-founder of NET Recovery and co-author of the study.
Elle Communications' team of experts was brought on to establish the brand as a trusted, visionary force transforming the recovery landscape, reframing public, medical, and cultural conversations around what's possible in opioid withdrawal management and relapse prevention. Before activating any PR or launch strategy, Elle conducted an extensive, standalone message-testing project that included designing and facilitating focus groups in key markets nationwide, an engagement NET Recovery sought out specifically due to Elle's expanding leadership and recognized expertise in this area. This work reflects the agency's growing portfolio of message-testing and audience-insight initiatives across the addiction, behavioral health, and social impact sectors, a specialty that continues to be a major area of growth for the firm.
Building on these insights, Elle is now deploying a full suite of strategic communications services to support the brand's national launch and long-term influence, including high-impact PR and media relations, thought-leadership development for executive voices, funding and investor-facing announcement strategy, and integrated storytelling campaigns designed to accelerate adoption and cultural change. Through this work, Elle ensures NET Recovery speaks directly to the needs, motivations, and concerns of diverse stakeholders-from people in recovery and medical professionals to payors, policymakers, public advocates, and the investment community-creating narratives that resonate, drive trust, and mobilize action.
As the company expands nationally, NET Recovery's new treatment program brings the NET Device™ directly to individuals in recovery through a secure, guided model designed to reduce barriers of cost, geography, and stigma. The rollout allows patients to access non-pharmacologic withdrawal relief and early stabilization support from home for the first time.
About Elle Communications
Elle Communications, a subsidiary of Dolphin Entertainment, is a leading PR agency with headquarters in Los Angeles and New York City. As early pioneers in impact PR, we are trusted by mission-driven businesses, nonprofit organizations, and some of the most respected public figures in social and environmental impact. For nearly two decades, our team of seasoned experts-deeply connected in media, talent and influencer relations, communications strategy, media training, affiliate marketing, and thought leadership-has amplified stories of progress, innovation, and the changemakers driving it. At Elle, we are committed to creating a supportive and empowering workplace while helping to build a stronger community, a more just society, and a better world. Learn more at www.ellecomm.com.
About Dolphin
Dolphin (NASDAQ:DLPN) is where cultural creation meets marketing execution. Founded in 1996 by Bill O'Dowd, Dolphin operates as both a venture studio-developing and investing in breakthrough content, products, and experiences-and a marketing consortium, featuring leading agencies across every communications discipline.
At its core, the venture studio creates, produces, finances, markets, and promotes new businesses and cultural ideas - ranging from acclaimed film, television, and digital content to consumer goods, live events and partnerships that define entertainment and lifestyle. Surrounding this entrepreneurial engine, Dolphin's marketing prowess brings together best-in-class firms including 42West, The Door, Shore Fire Media, Elle Communications, Special Projects and The Digital Dept. Together, this collective delivers unmatched cross-marketing expertise and relationships across every vertical of pop culture - from film, television, music, influencers, sports, hospitality, and fashion to consumer brands and purpose-driven initiatives. Dolphin marketing has been the recipient of many accolades, including #1 Agency of the Year on the Observer PR Power List in 2025, The PR Net 100, and the PR News Elite 120.
Follow us on Instagram here.
CONTACT:
James Carbonara
HAYDEN IR
(646)-755-7412
james@haydenir.com
1 The NET Device is a transcutaneous alternating current stimulator (tACS) that is intended to be used in patients experiencing opioid withdrawal in conjunction with standard symptomatic medications and other therapies for opioid withdrawal symptoms under the supervision of trained clinical personnel.
2 https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1627267/full
SOURCE: Dolphin Entertainment
View the original press release on ACCESS Newswire
FAQ
What did Dolphin (DLPN) announce on November 19, 2025 about NET Recovery?
What evidence supports NET Device efficacy reported in the November 19, 2025 release?
Is the NET Device FDA-approved for stimulant addiction according to the November 19, 2025 release?
How will NET Recovery's national program change access as described on November 19, 2025?
What services will Elle Communications provide for NET Recovery's launch?
Where was the NET Device study published and what timeline did it report?
